Derivative of nucleoside reverse transcriptase inhibitor (intravitreal)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Derivative of nucleoside reverse transcriptase inhibitor (intravitreal), covering 2024-11-01 to 2024-11-01. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase Inhibitor in Subjects with Diabetic Macular Edema [Phase 1]